Testing ABSK131 for advanced solid tumors with a specific genetic change
Part of Cancer clinical trials.
This trial tests a new drug called ABSK131 in people whose cancer has a missing MTAP gene. It is for advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your tumor must have a specific genetic change called a homozygous MTAP deletion or loss of MTAP.
- You must have advanced cancer that has not responded to standard therapy or no standard therapy exists.
- You must have at least one measurable tumor (by imaging) and be well enough to be up and about (ECOG 0 or 1).
- You must not have received certain previous treatments, like PRMT5 or MAT2A inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ABSK211 in people with advanced solid tumors that have a change in the KRAS gene. The goal is to see if the drug is safe and works against the cancer.
This study tests a new drug called ABSK141 for people with advanced solid tumors that have a specific mutation called KRAS G12D. It aims to see if the drug can shrink or control the cancer, and it has different phases for different groups of patients.
This trial tests a new drug called ABSK021 for people with advanced pancreatic cancer who have not received any prior treatment. It aims to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests an experimental pill called SY-9453 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if it is safe and how the body processes it. It may be an option if you have tried standard treatments without success.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
Hear when a new Solid Tumors (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.